Hemab Therapeutics Holdings, Inc. COAG
At closeNov 13, 2026, 4:26 PM EST
After hours · Nov 13, 4:26 PM ET
- YTD
- +20.18%
- 1 year
- +20.18%
- Market cap
- 1.91B
- EPS (ttm)
- -3.55
- Shares out
- 46.71M
- Forward P/E
- -15.66
- YTD return
- +20.18%
- 1-year return
- +20.18%
- Volume
- 401.09K
- Avg volume
- 489.69K
- Open
- 39.37
- Previous close
- 39.38
- Day's range
- 38.44 – 41.27
- 52-week range
- 24.98 – 54.94
- Analysts
- Strong Buy
- Price target
- 63.00 (+54.2%)
- Earnings date
- Feb 9, 2027
5D -8.29 (-16.95%)
Key statistics
- Enterprise value
- 1.41B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 430.24M
- Total debt
- 965.00K
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 37.12
- 200-day average
- 37.17
Analyst view
Consensus: strong buy
- Target (low)
- 54.00
- Target (mean)
- 63.00
- Target (high)
- 70.00
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 9, 2027
Expected Feb 9, 2027. Consensus EPS estimate -0.54912.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 9, 2027 | Dec 30, 2026 | -0.59 | — | — | — |
| Nov 10, 2026 | Sep 30, 2026 | -0.50194 | -0.58 | -0.08 | -15.55% |
| Aug 11, 2026 | Jun 30, 2026 | -0.7325 | -0.80 | -0.07 | -9.22% |
| May 21, 2026 | Mar 31, 2026 | -23.25 | -23.98 | -0.73 | -3.16% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2026 | LifeSci Capital | init | — | Outperform |
| Oct 15, 2026 | JP Morgan | init | — | Overweight |
| Oct 12, 2026 | Rodman & Renshaw | init | — | Buy |
| Aug 12, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 13, 2026 | Jefferies | main | Buy | Buy |
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- hemab.com
News
Hemab Therapeutics to Participate in Upcoming Investor Conferences 
Hemab Therapeutics Holdings, Inc. (COAG) Q3 2026 Earnings Call Transcript 
What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call 
Hemab Therapeutics Hldgs Q3 2026 Earnings Call Transcript 
Hemab Therapeutics Hldgs Q3 EPS $(0.58) Misses $(0.52) Estimate 
Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test - LifeSci Capital Initiates Coverage On Hemab Therapeutics Hldgs with Outperform Rating, Announces Price Target of $65
Hemab Therapeutics Initiates SOLARA, Pivotal Phase 3 Trial Evaluating Sutacimig As Potential Prophylactic Treatment For People With Glanzmann Thrombasthenia 
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
Your note
Sign in to keep a note on COAG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MARAGANORE JOHN M | Director | Conversion of Exercise of derivative security | May 3, 2026 | 35,948 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | May 3, 2026 | 4,180,550 |
| RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 11, 2026 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 15, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 16.72% | 7,808,627 | 319.06M | Jun 29, 2026 |
| Novo Holdings A/S | 8.95% | 4,180,550 | 170.82M | Jun 29, 2026 |
| FMR, LLC | 7.92% | 3,697,837 | 151.09M | Jun 29, 2026 |
| Capital International Investors | 7.72% | 3,603,876 | 147.25M | Jun 29, 2026 |
| Deep Track Capital, Lp | 7.71% | 3,602,093 | 147.18M | Jun 29, 2026 |
| Siren, L.L.C. | 4.47% | 2,086,834 | 85.27M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 7.50% | 3,506,543 | 143.28M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.19% | 555,543 | 22.70M | Jun 29, 2026 |
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 1.14% | 531,382 | 21.71M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.12% | 523,853 | 21.40M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.10% | 514,858 | 21.04M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.08% | 506,791 | 20.71M | Sep 29, 2026 |